Ani Pharmaceuticals (ANIP) Depreciation & Amortization (CF) (2010 - 2026)

Ani Pharmaceuticals has disclosed Depreciation & Amortization (CF) across 17 years of filings, most recently posting $20.9 million for Q1 2026.

• Depreciation & Amortization (CF) for Q1 2026 came in at $20.9 million, down 8.61% year-over-year; the trailing twelve-month figure through Mar 2026 was $89.4 million (up 17.79% YoY), and the FY2025 annual result was $91.4 million, up 34.97% from the prior year.
• Depreciation & Amortization (CF) came in at $20.9 million for Q1 2026 at Ani Pharmaceuticals, down from $22.6 million in the prior quarter.
• In the past five years, Depreciation & Amortization (CF) ranged from a high of $23.3 million in Q2 2025 to a low of $12.9 million in Q4 2022.
• The 5-year median for Depreciation & Amortization (CF) is $15.2 million (2023), against an average of $17.4 million.
• Across the five-year window, Depreciation & Amortization (CF) jumped 58.41% in 2025 and dropped 8.61% in 2026, its largest moves.
• Ani Pharmaceuticals' Depreciation & Amortization (CF) stood at $12.9 million in 2022, then climbed by 17.87% to $15.2 million in 2023, then surged by 48.74% to $22.6 million in 2024, then increased by 0.06% to $22.6 million in 2025, then decreased by 7.49% to $20.9 million in 2026.
• The last three Depreciation & Amortization (CF) figures came in at $20.9 million (Q1 2026), $22.6 million (Q4 2025), and $22.6 million (Q3 2025), per Business Quant data.